{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:47:29Z","timestamp":1794271649440,"version":"4.9.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.annonc.2023.07.001","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T11:42:30Z","timestamp":1689594150000},"page":"907-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":254,"title":["Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial"],"prefix":"10.1016","volume":"34","author":[{"given":"E.","family":"Felip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Altorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Valli\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mart\u00ednez-Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rittmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Goloborodko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Belleli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Gitlitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.annonc.2023.07.001_bib1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","article-title":"Current status of immune checkpoint inhibition in early-stage NSCLC","volume":"30","author":"Vansteenkiste","year":"2019","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2023.07.001_bib2","first-page":"5614","article-title":"Neoadjuvant and adjuvant immunotherapy in early-stage non-small-cell lung cancer, past, present, and future","volume":"10","author":"Szeto","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.annonc.2023.07.001_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2023.07.001_bib4","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.07.001_bib5","first-page":"CD011430","article-title":"Adjuvant chemotherapy for resected early-stage non-small cell lung cancer","volume":"3","author":"Burdett","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"10.1016\/j.annonc.2023.07.001_bib6","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2023.07.001_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","article-title":"Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC","volume":"17","author":"Wu","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2023.07.001_bib8","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.annonc.2023.07.001_bib9","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2023.07.001_bib10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2023.07.001_bib11","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2023.07.001_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10308","key":"10.1016\/j.annonc.2023.07.001_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.annonc.2023.07.001_bib14","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.annonc.2023.07.001_bib15","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.annonc.2022.02.090","article-title":"800 Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study","volume":"33","author":"Felip","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.07.001_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.lungcan.2018.06.007","article-title":"Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS)","volume":"124","author":"Andreas","year":"2018","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2023.07.001_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cllc.2014.12.010","article-title":"Treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small cell lung cancer at US community oncology practices","volume":"16","author":"Buck","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"14","key":"10.1016\/j.annonc.2023.07.001_bib18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/1759-7714.14007","article-title":"Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study","volume":"12","author":"Cai","year":"2021","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2023.07.001_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jval.2010.10.006","article-title":"Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003","volume":"14","author":"Cipriano","year":"2011","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.annonc.2023.07.001_bib20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"10.1016\/j.annonc.2023.07.001_bib21","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.07.001_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8581","article-title":"EA5142 adjuvant nivolumab in resected lung cancers (ANVIL)","volume":"36","author":"Chaft","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2023.07.001_bib25","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s12325-021-01675-0","article-title":"Curative-intent treatment with durvalumab in early-stage cancers","volume":"38","author":"Melillo","year":"2021","journal-title":"Adv Ther"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423007640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423007640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:16:20Z","timestamp":1760336180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423007640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0923753423007640"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.07.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}